Navigation Links
Breakthrough in cancer vaccine research
Date:11/4/2010

Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed.

New research, published today in the journal Science, reveals that a type of stromal cell found in many cancers which expresses fibroblast activation protein alpha (FAP), plays a major role in suppressing the immune response in cancerous tumours thereby restricting the use of vaccines and other therapies which rely on the body's immune system to work. They have also found that if they destroy these cells in a tumour immune suppression is relieved, allowing the immune system to control the previously uncontrolled tumour.

Douglas Fearon, Sheila Joan Smith Professor of Immunology of the Department of Medicine at the University of Cambridge, said: "Finding the specific cells within the complex mixture of the cancer stroma that prevents immune killing is an important step. Further studying how these cells exert their effects may contribute to improved immunological therapies by allowing us to remove a barrier that the cancer has constructed."

Vaccines created to prompt the immune system to attack cancerous cells in tumours have shown to activate an immune response in the body but have, inexplicably, almost never affected the growth of tumours. Immunologists who specialise in tumours have suspected that within the tumour microenvironment the activity of immune cells is somehow suppressed, but they have thus far been unable to fully reverse this suppression.

The new research, funded by the Wellcome Trust and the Sheila Joan Smith Professorship endowment, sheds light on why the immune response is suppressed. The Cambridge study found that at least one immune suppressive component is contained within normal tissue cells (called stromal cells) the cancer has coerced to assist its survival. The cell they studied specifically expresses a unique protein often associated with wound healing - fibroblast activation protein alpha (FAP). The FAP expressing cells are found in many cancers, including breast and colorectal cancers.

In order to determine if FAP expressing stromal cells contribute to the resistance of a tumour to vaccination, the researchers created a transgenic mouse model which allowed them to destroy cells which expressed FAP. When FAP-expressing cells were destroyed in tumours in mice with established Lewis lung carcinomas (of which only 2% of the tumour cells are FAP-expressing), the cancer began to rapidly 'die'. The Fearon lab now hopes to collaborate with scientists at the CRUK Cambridge Research Institute to evaluate the effects of depleting FAP-expressing cells in a mouse model that more closely resemble human cancer, and to examine FAP-expressing cells of human tumours.

Professor Fearon continued: "These studies are in the mouse, and although there is much overlap between the mouse and human immune systems, we will not know the relevance of these findings in humans until we are able to interrupt the function of the tumour stromal cells expressing FAP in patients with cancer.

"It should be noted, however, that the FAP-expressing stromal cell was actually first found in human cancer by Lloyd Old and his colleagues 20 years ago."


'/>"/>

Contact: Genevieve Maul
Genevieve.maul@admin.cam.ac.uk
44-012-237-65542
University of Cambridge
Source:Eurekalert

Related medicine news :

1. Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeants Pet Care Products, Inc.
2. First Breakthrough in Water Heating Technology!
3. New DNA technique leads to a breakthrough in child cancer research
4. Northern Illinois Proton Center on the Verge of Major Medical Breakthrough
5. OvaCue Fertility Monitor Breakthrough Allows Women to See Fertility Color-coded on a Calendar Over Time
6. National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
7. Breakthroughs in treatment of spine and back conditions
8. buySAFE, Inc. Releases a Breakthrough White Paper that is a Must Read for Every Internet Retailer Interested in Increasing Website Conversion
9. Tampa Bay Vein Treatment and Cosmetic Dermatology Practice Using New Laser Technology Some Say is the Latest Breakthrough
10. Breakthrough for babies born with severe cleft palates after experiments at ISIS
11. Gene-Targeted Cancer Fix Could Be a Breakthrough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... Facing medical ... father Ezra Clark is taking advantage of a new benefit for employees that is ... means a lot that the company supports me and other employees as new parents. ...
(Date:7/24/2017)... ... July 24, 2017 , ... ...      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, ... celebrate the structural topping out of the new Destination Medical Building located ...
(Date:7/24/2017)... TX (PRWEB) , ... July 24, 2017 , ... ... under the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted ... of California Department of Health Care Services, will facilitate the development of a ...
(Date:7/24/2017)... ... ... The International Essential Tremor Foundation (IETF) will host a free educational forum in ... take place on Saturday, Aug. 26 at the Embassy Suites by Hilton Cleveland Rockside ... a.m. to 12 p.m., with check-in beginning at 8 a.m. The event is sponsored ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... already work hand-in-hand on an Innovation Collaboration program, have signed a five-year agreement ... and cost of the care members and patients receive. The agreement also signifies ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/10/2017)... July 10, 2017 Locus Biosciences Inc. today ... support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for ... leading Chinese Internet services provider, and joined by the ... infectious disease product programs targeting antibiotic resistant infections and ... Founded by Dr. Rodolphe Barrangou and Dr. ...
(Date:7/5/2017)... , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company focused ... that it has received approval from the Israel Securities Authority ... Exchange (TASE). Oramed common stock will commence trading on the ... on the current market capitalization of the Company, it is ...
Breaking Medicine Technology: